597 related articles for article (PubMed ID: 27086681)
21. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
22. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.
Schreml J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1538-1548. PubMed ID: 28618994
[TBL] [Abstract][Full Text] [Related]
23. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
[TBL] [Abstract][Full Text] [Related]
24. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
Nozue T
J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
[TBL] [Abstract][Full Text] [Related]
25. Consensus statement of professional associations on prescribing of PCSK9-inhibitors.
Češka R; Táborský M; Vrablík M
Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246
[TBL] [Abstract][Full Text] [Related]
26. Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia.
Robinson JG
Prog Cardiovasc Dis; 2016; 59(2):165-171. PubMed ID: 27498088
[TBL] [Abstract][Full Text] [Related]
27. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
[TBL] [Abstract][Full Text] [Related]
29. [PCSK9 inhibitors : Recommendations for patient selection].
Laufs U; Custodis F; Werner C
Herz; 2016 Jun; 41(4):296-306. PubMed ID: 27207595
[TBL] [Abstract][Full Text] [Related]
30. PCSK9 inhibition in the management of familial hypercholesterolemia.
Ogura M
J Cardiol; 2018 Jan; 71(1):1-7. PubMed ID: 28784313
[TBL] [Abstract][Full Text] [Related]
31. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.
Choi J; Khan AM; Jarmin M; Goldenberg N; Glueck CJ; Wang P
Lipids Health Dis; 2017 Jul; 16(1):141. PubMed ID: 28738813
[TBL] [Abstract][Full Text] [Related]
33. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
Stein EA
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553
[TBL] [Abstract][Full Text] [Related]
34. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
[TBL] [Abstract][Full Text] [Related]
35. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
Sible AM; Nawarskas JJ; Anderson JR
Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466
[TBL] [Abstract][Full Text] [Related]
36. [Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy].
Wallemacq C
Rev Med Liege; 2017 Nov; 72(11):505-512. PubMed ID: 29171950
[TBL] [Abstract][Full Text] [Related]
37. New concepts in the management of dyslipidaemiaa.
Gencer B; Rodondi N; Mach F
Swiss Med Wkly; 2016; 146():w14378. PubMed ID: 27878791
[TBL] [Abstract][Full Text] [Related]
38. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
[TBL] [Abstract][Full Text] [Related]
39. Alirocumab: targeting PCSK9 to treat hypercholesterolemia.
Pećin I; Reiner Ž
Drugs Today (Barc); 2015 Dec; 51(12):681-7. PubMed ID: 26798848
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia.
Cicero AFG; Bove M; Borghi C
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):9-15. PubMed ID: 29231064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]